Navigation Links
New Study Identifies Better Solution for Itch
Date:4/3/2013

SAN DIEGO, April 3, 2013 /PRNewswire/ -- Shoppers spend more than $352 million annually on anti-itch remedies and they are faced with a wealth of options of over-the-counter products on store shelves.  A new study published in the international peer-reviewed journal, Acta Dermato-Venereologica, may just help itch sufferers zero in on the most effective remedies.

(Photo: http://photos.prnewswire.com/prnh/20130313/CG76729)

Researchers at the Wake Forest School of Medicine compared a topical hydrogel containing aluminum acetate and strontium (sold commercially as TriCalm Hydrogel) head-to-head against two products commonly marketed for anti-itch; hydrocortisone and diphenhydramine (Benadryl 1%).  TriCalm was "significantly superior" to the other two over-the-counter anti-itch agents reducing both the peak intensity and duration of the subjects' itch, according to the results of the study.

"Managing itch, especially chronic itch, is challenging," said Gil Yosipovitch, MD, of the Dermatology Department at Wake Forest University and one of the study's authors. "Many of the typical over-the-counter remedies are not effective and what this study tells us is that TriCalm products are likely a more effective solution than other over-the-counter options."

The double blinded, vehicle-controlled study was looking specifically at non-histamine induced itches.  The researchers induced itch in the subjects using a tropical plant called cowhage typically used when studying non-histamine-induced itch, This type of itch is more related to chronic itch, where antihistamines do not have any anti-itch effect.

New TriCalm Hydrogel is steroid-free and is now available at Walgreens, CVS and other retailers.

TriCalm is a product of Cosmederm Bioscience, a specialty pharmaceutical company focused on dermatology and pain management. Drawing on years of laboratory research and published clinical work, Cosmederm develops products that target a wide variety of skin diseases and inflammatory conditions. With its portfolio of patented analgesic and anti-inflammatory compounds, Cosmederm has developed uniquely effective topical products ranging from cosmeceuticals and OTC drugs to a pipeline of prescription drug candidates. Cosmederm is the sole owner of COSMEDERM-7, a patented compound made from strontium that has been developed for dermatological applications. Cosmederm's product lines include TriCalm™, REFINITY™ Skin Solutions, and COSMEDERM SKIN SCIENCE™.


'/>"/>
SOURCE Cosmederm Bioscience
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Study Finds Utilizing Integrated Medical and Pharmacy Data Improves Ability to Forecast Use of High-cost Specialty Treatments
2. Study Showed Patients Treated With The miraDry© System Experienced 82 Percent Sweat Reduction On Average
3. Asubio Initiates Landmark Clinical Study in Spinal Cord Injury
4. New Veridex Alliance Drives Study Of Circulating Tumor Cells In Men With Metastatic Prostate Cancer
5. Shingles Vaccine is Safe, According to New Study
6. Structural Trends to Profoundly Change Life Sciences Industry, Genpact Study Shows
7. Argos Therapeutics Secures $25 million Series D Financing to Commence Phase 3 ADAPT Study in Patients with Metastatic Renal Cell Carcinoma (mRCC) in Mid-2012
8. Anthera Announces the Completion of Patient Dosing in Phase 2b PEARL-SC Study
9. Omthera Pharmaceuticals Announces Positive Top-Line Results from Phase 3 EVOLVE Study
10. Accuray Launches First Study to Compare CyberKnife® SBRT to Surgery and IMRT for Treatment of Early-Stage Prostate Cancer
11. Interim results of VITOBA™ (VImpaT® added to One Baseline AED) Study Presented at the 64th Annual Meeting of the American Academy of Neurology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... , June 23, 2016 Leading ... that address medical conditions resulting from a breakdown ... has appointed Greg Doyle as chief ... Leading BioSciences, executive management team and board of ... chief financial officer. He will provide continued leadership ...
(Date:6/23/2016)... June 23, 2016 Research and ... in Europe 2016 Edition: The New Global Agenda " ... OTC Distribution in Europe - ... explores and tracks change. It identifies the driving factors coming ... the consumer healthcare industry now and in the future. It ...
(Date:6/23/2016)... June 23, 2016 The ... the development of combination therapies trend is expected ... treatment of CLL were available only in the ... are chlorambucil in combination with prednisone, and a ... a growing trend of developing combination therapies to ...
Breaking Medicine Technology:
(Date:6/24/2016)... San Diego, CA (PRWEB) , ... June 24, 2016 , ... ... up with the American Cancer Society and the Road To Recovery® program to drive ... care to seniors and other adults to ensure the highest quality of life and ...
(Date:6/24/2016)... Norcross, Georgia (PRWEB) , ... June 24, 2016 ... ... Year” awards today at the Clinical Decision Making in Emergency Medicine conference in ... who have authored journal articles published in Emergency Medicine Practice and ...
(Date:6/24/2016)... ... 2016 , ... Strategic Capital Partners, LLC (SCP) in concert ... capital for emerging technology companies. SCP has delivered investment events and professional ... than a million dollars of capital investment for five companies. The ...
(Date:6/24/2016)... ... June 24, 2016 , ... Today, ... stem (iPS) cells and other difficult to transfect cells, announces its launch of ... PluriQ™ G9™ Gene Editing System is a complete system for culturing and ...
(Date:6/24/2016)... ... June 24, 2016 , ... To succeed under value-based payments, ... are unsure how to move forward, given the need to sustain current operations. ... tailored to an organization’s specific needs. , PYA Principal Martie Ross states, “Healthcare ...
Breaking Medicine News(10 mins):